Takeda Pharmaceuticals competitive analysis

Explore patent oppositions filed by Takeda Pharmaceuticals against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 27, 2026
Patent NumberTitleApplicantOpposition Date
Stable Liquid FibrinogenLABORATOIRE FRANAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESJun 5, 2024
Improved Process For The Preparation Of Immunoglobulin G (Igg)BIO PRODUCTS LABORATORYMay 29, 2019
Immunoglobulin G (Igg) Concentrate Depleted Of Anti-A And Anti-B Antibodies And Of Polyreactive IggsLABORATOIRE FRANAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESApr 11, 2019
Purified Mesenchymal Stem Cell Compositions And Methods Of Purifying Mesenchymal Stem Cell CompositionsMESOBLASTJul 5, 2017

Explore Takeda Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleTotal Oppositions
Nov 12, 2014Methods For Concomitant Treatment Of Theophylline And Febuxostat6

Latest PTAB cases involving Takeda Pharmaceuticals

Discover the latest PTAB cases involving Takeda Pharmaceuticals, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Takeda Pharmaceuticals with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
TAKEDA PHARMACEUTICALS4 - - -
BIO PRODUCTS LABORATORY - 1 - -
LABORATOIRE FRANAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES - 20 - -
LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES SOCIETE ANONYME - 3 - -